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Cross-protectionThe immunization of poultry where H5 and H7 influenza viruses (IVs) are endemic is one of the strategies
to prevent unexpected zoonoses. Our group has been focused on conserved HA-epitopes as potential vac-
cine candidates to obtain multivalent immune responses against distinct IV subtypes. In this study, two
conserved epitopes (NG-34 and CS-17) fused to flagellin were produced in a Baculovirus platform based
on Trichoplusia ni larvae as living biofactories. Soluble extracts obtained from larvae expressing ‘‘flagellin-
NG34/CS17 antigen” were used to immunize chickens and the efficacy of the vaccine was evaluated
against a heterologous H7N1 HPAIV challenge in chickens. The flagellin-NG34/CS17 vaccine protected
the vaccinated chickens and blocked viral shedding orally and cloacally. Furthermore, no apparent clin-
ical signs were monitored in 10/12 vaccinated individuals. The mechanism of protection conferred is
under investigation.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The high pathogenic avian influenza viruses (HPAIV), mainly H5
and H7 subtypes, are devastating pathogens in poultry. On occa-
sions, however, they have spilt over into humans [1] fortunately,
with limited evidence of being capable of transmitting between
humans. Nevertheless, the risk of an occurring reassortant IV that
may cross the human-to-human transmission barrier is threaten-
ing the public health.
Controlled vaccination campaigns in some endemic countries
may prevent possible outbreaks caused by avian IVs in the poultry.
At present, most of the poultry influenza vaccines are inactivated-
typed but also there are licensed recombinant and live-attenuated
vaccines [2]. Nevertheless, recombinant vaccines overcome many
shortcomings from the inactivated-typed vaccines [3–5]. In the
present study, Baculovirus were selected as a suitable influenza
vaccine technology platform. As biofactories, insect larvae fromTrichoplusia ni (T.ni), were used for recombinant protein production
[6]. Besides, a novel baculovirus vector expression cassette, Top-
Bac, was used to optimize the baculovirus expression vector sys-
tem (BEVS) [7].
Having potent antigenic properties, hemagglutinin (HA) is the
most selected recombinant protein from IVs due to its potent anti-
genic properties favoring antibodies which can prevent IVs infec-
tion [8]. Our research group has been dedicated to use conserved
HA-epitopes as vaccine candidates [9,10]. Thus, two in silico pre-
dicted conserved HA-epitopes from H1 (peptide NG-34) and from
H5 (peptide CS-17) were selected. Both epitopes were fused to
phase 2 flagellin from Salmonella typhymurium to improve the
immunogenicity of the vaccine [11,12]. The final formulation
(flagellin-NG34/CS17) was produced in the Baculovirus system
and the soluble extracts obtained expressing flagellin-NG34/CS17
were used as a vaccine against IVs infection in chicken. The final
goal of this work was to study the vaccine efficacy of soluble
extracts expressing flagellin-NG34/CS17 construct against a
heterologous virus challenge in chicken.
Our results indicate that chickens immunized twice with
flagellin-NG34/CS17 were protected against a lethal challenge with
a heterologous IV (H7 subtype). Immunized animals showed no
M. Sisteré-Oró et al. / Vaccine 38 (2020) 416–422 417clinical signs of infection and did not shed virus. An increased IgM/
IgY was also evident in some of the vaccinated chicken.
2. Materials and methods
2.1. Immunogen, construction of recombinant baculovirus and
infection of insect larvae
Table 1 depicts the aminoacidic sequence of the two conserved
HA-epitopes (NG-34 and CS-17) used in the vaccine approach,
which are connected by the linker sequence: SSGSSGSSGSS. At
the N-terminal site of that sequence, the complete sequence of Sal-
monella typhimurium phase 2 flagellin (GenBank: AAC94993.1) was
inserted. Moreover, a 6-His tag was added at the C-terminal site of
the NG34/CS17 sequence. The whole cDNA was chemically synthe-
sized (GenScript, Piscataway, NJ, USA) (Fig. 1). The codon usage
from Bombyx mori was utilized to optimize the sequence to
improve the epitope expression in the T.ni larvae: (http://www.
ebi.ac.uk/Tools/st/emboss_backtranseq/). The whole sequence of
interest was excised from the pCDNA3.1(+) vector and inserted in
the TopBac3.2 vector (Algenex, Madrid, Spain). The resulting
donor plasmid was used to generate the corresponding recombi-
nant baculovirus (rBac) by using the Bac-to-Bac Baculovirus
Expression System (Invitrogen, San Diego, CA, USA). Baculovirus
obtained were titrated in duplicate by a standard plaque protocol
(Invitrogen, No. MAN0000414). Virus titer was determined as
plaque-forming units (PFU). T.ni larvae in stage of fifth-instar lar-
vae were sedated and injected with 5 mL of the recombinant bac-
ulovirus diluted with TNM-FH medium (PAN Biotech GmbH,
Aidenbach, Germany) to reach a dose of 5.5x106 pfu/mL.
2.2. Protein extraction, determination and quantification
Total soluble protein (TSP) extract from T. ni larvae infected
with the rBac was obtained by mixing extraction buffer (PBS 1X,
Brij35 0.1%: BR00171000; PMSF 1 mM and DTT 5 mM) per gram
of larvae biomass and homogenizing twice (total protein extract,
TP). Sonication, centrifugation and filtration of supernatants with
a 22 lM Miracloth filter paper (Calbiochem, Merck, Darmstadt,
Germany) (total soluble protein extract, TSP) was carried out. Sam-
ples were resolved in gels both for Coomassie blue staining and
Western blots. Transferred membranes were incubated with an
anti-His monoclonal antibody (Clontech, Mountain View, CA,
USA) diluted 1:2000 in PBST followed by incubation with an
anti-mouse IgG horseradish peroxidase (HRP)-labeled conjugate
(GE Healthcare, Marlborough, MA, USA) diluted 1:2000 in PBST.
All membranes were developed using ECL (Enhance Chemilumi-
nescence) reagent. Images were captured by ChemiDocTM XRS Gel
Imaging System (Bio-Rad, USA) and analyzed using the
ImageLabTM Software (Bio-Rad, version 6).Table 1




Aa positions referenced are in accordance with the reference cited from the GenBank da
Fig. 1. Illustration of the sequence of interest and resTotal protein concentration of the extract was determined by
the Bradford method (Bio-Rad, USA) [13] and the quantification
of the flagellin-NG34/CS17 expressed in T. ni larvae was developed
by measurement of band densitometry in Western Blot images
using a standard curve with a known quantified 6xHis-tagged pro-
tein (ASFV p54 protein).2.3. Cells, virus and antigen
Spodoptera frugiperda Sf21 cell line (Invitrogen, USA) was
cultured at 27 C in TNM-FH medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (PAN Biotech GmbH,
Germany) and gentamicin (50 mg/mL) (PAN Biotech GmbH,
Germany).
Madin-Darby Canine Kidney (MDCK, ATCC CCL-34) cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% FBS, 1% penicillin/streptomycin and 1%
L-glutamine.
A/chicken/Italy/5093/99 H7N1 HPAIV strain was kindly pro-
vided by Dr. Moreno (Brescia, Italy) and was propagated in 11-
day-old embryonated specific pathogen free (SPF) chicken eggs.
Allantoic fluid was collected after 48–72 h of inoculation, filtered
(0.45 mM) and diluted ten-fold in PBS for titration in SPF eggs [14].
The H7 protein (A/turkey/Italy/4602/99 (H7N1)) used was pur-
chased from Sino Biological, Beijing, China (cat no. 40169-V08H1).2.4. Ethics statement, experimental design and pathological
assessment
All chickens were handled according to procedures approved by
the IRTA Ethics Committee for Animal Experimentation and the
Animal Experimentation Commission from the Autonomous Com-
munity of Catalonia Government. Additionally, the study was in
accordance with the Directive, UE 63/2010; the Spanish Legisla-
tion, RD 53/2013; the Catalan Law 5/1995 and Decree 214/1997.
Thirty-four SPF chickens were randomly divided in three differ-
ent negative isolators with HEPA-filtered air under biosafety level
3 (BSL-3) containment conditions at IRTA-CReSA. Throughout the
experiment, chickens were feed with food and water ad libitum.
One isolator (group A = animals 1–12) was used as negative control
and individuals were subcutaneously sham-vaccinated with PBS
mixed 70:30 with MontanideTM 71 VG ISA. Chickens in the second
isolator (group B = 13–24) were vaccinated at 10 days of age with
flagellin-NG34/CS17 and, after 21 days of interval, a boost vaccina-
tion followed. In parallel, in the third isolator (group C = 25–34)
chickens were immunized only once with flagellin-NG34/CS17
(without receiving boost vaccination). The animals from Group B
and C were subcutaneously vaccinated with 0.250 mL/animal of
soluble larvae extracts containing 15 mg/mL of flagellin-NG34/
CS17 and mixed in a ratio of 70:30 with MontanideTM 71 VG ISA.ach.
Consensus virus subtype GenBank Id
pH1N1 ACS36215
H5N1 AAC32098.1
tabase. Abbreviations: aa = amino acid; HA = hemagglutinin; Id = identification.
triction sites inserted in the pCDNA3.1(+) vector.
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lated with 100 mL diluted infectious allantoic fluid containing 104.5
ELD50 H7N1 HPAIV. Two days pre-challenge onwards all the chick-
ens were monitored daily for flu-like clinical signs. The experiment
terminated at 10 days post-infection (dpi), when all the remaining
chickens were euthanized. Oropharyngeal (OS) and cloacal swabs
(CS) samples were collected at 1, 2, 3, 5, 7 and 9 dpi. Blood samples
were collected previous to the challenge (33 post-vaccination day
(PVD)) and at 10 dpi.
Daily monitoring for clinical signs was carried out according to
World Organization for Animal Health (OIE) guidelines [15] and a
semi-quantitative scoring: healthy (0), sick (1), severely sick (2),
moribund or dead (3) was established. Chickens presenting one
of the potential flu-clinical signs were classified as sick (1) chickens
manifested two or more of the potential flu-clinical signs were
classified as severely sick (2) and were euthanized by inoculating
intravenously sodium pentobarbital.
2.5. Quantitative real time (RT-qPCR)
Viral RNA was extracted from OS and CS using the kit NucleoS-
pin RNA isolation kit (Macherey-Nagel GmbH&CoKG, Düren, Ger-
many), and a fragment of the M gene amplified [16] in Fast7500
equipment (Applied Biosystems, Foster City, CA, USA). The detec-
tion limit of the technique was 0.84 log10GEC/mL viral RNA
copies/sample.2.6. H7-specific enzyme-linked immunosorbent assays (ELISAs),
hemagglutination inhibition (HI) assay and serum neutralization test
(SNT)
ELISA plates were coated with 2 mg/mL of H7 protein antigen.
Plates were blocked and diluted 1:100 chicken sera were later
incubated during 1 h at 37 C followed with either diluted
1:50000 HRP-conjugated goat anti-chicken IgY (ab6877, Abcam,
Cambridge, UK) or diluted 1:50000 HRP-conjugated goat anti-
chicken IgM (ab112813, Abcam, UK). After further washing steps,
3, 30, 5, 50-tetramethylbenzidine (TMB) substrate solution was dis-
pensed and the reaction was stopped with 1 N H2SO4. Plates were
finally read at an optical density (OD) of 450 nm.
HI tests were developed according standard protocols [15]. For
SNT, plates containing 5 * 104cells/well (MDCKs) were seeded and
incubated overnight. Chicken inactivated sera sampleswere serially
diluted up to 1: 2560 and incubated with the H7N1 virus (100Fig. 2. Production of recombinant flagellin-NG34/CS17 protein in T. ni larvae (A) Cooma
(10 mL loaded/lane) obtained from empty rBac TB3.2-Ni (a recombinant TopBac baculovi
(lane 2: TP, lane 4: TSP) infected T. ni larvae run in a 10% SDS-PAGE gel. Arrow indicates
MW: BenchMarkTM Unstained Protein Ladder (Invitrogen, USA). (B) Quantification by anti
the soluble larvae extract. Lanes: (1) TSP extract from empty rBac TB3.2-Ni infected T.
infected T. ni larvae (5 mL loaded), (3–8) p54-His standard curve (150, 100, 50, 40, 20, 10
CS17 and p54-His proteins. MW: See Blue Plus2 Prestained Ladder (Invitrogen, USA). (For
to the web version of this article.)TCID50/50 mL) during 2 h at 37 C and in a 5% CO2 atmosphere.
Serum-virus mixtures were then added to PBS1X washed MDCK
cells. Cytopathic effect (CPE) wasmonitored undermicroscope after
7 days.
In all assays (ELISA, HI, SNT), samples were evaluated in dupli-
cates and a positive H7N1 and negative control anti-serums (GD-
Animal Health Service, Deventer, Netherlands) were included in
each plate.
2.7. Statistical analysis
R statistical software was used for developing all the statistical
analysis (http://cran.r-project.org/). The test used for each tech-
nique as well as the significance found among the groups is
described at the corresponding figure captions.
3. Results
3.1. Production of recombinant flagellin-NG34/CS17 in T. Ni larvae
Fifth instars T. ni larvae were inoculated with 27,500 pfu of the
TB3.2 flagellin-NG34/CS17 baculovirus and total soluble protein
extract was obtained after 72 h of infection and analyzed by SDS-
PAGE andWestern blot (Fig. 2A). Flagellin-NG34/CS17 recombinant
protein was detected by Western blot as a major band of about
65 kDa. For immunization experiments the amount of flagellin-
NG34/CS17 antigen in the soluble larvae extract was quantified
by Western blot (Fig. 2B). Concentration was determined in
28.6 mg of flagellin-NG34/CS17 per mL of TSP larvae extract.
3.2. Immunization with flagellin-NG34/CS17 protected chickens
against heterologous IV challenge, saved chickens from flu-like
manifestations, limited oropharyngeal and cloacal H7N1 viral
shedding and induced an increase in IgM and improved IgY response
More than 91% (11/12) of the chickens vaccinated twice with
flagellin-NG34/CS17 survived against a challenge with H7N1
HPAIV until the end of the experiment. In contrary, only two ani-
mals (16.6%) survived from the unvaccinated group. Animals
which received only one vaccination also succumbed to infection
and, only two animals (22.2%) remained alive (Fig. 3A) at 10 dpi.
The majority of the chickens in the unvaccinated group and chick-
ens which received only one vaccination died between 5 and 8 dpi
(Fig. 3A).ssie blue staining (left) and anti-6xHis-tag Western Blot (right) of protein extracts
rus without a gene of interest) (lane 1: TP, lane 3: TSP) or rBac flagellin-NG34/CS17
the band corresponding to flagellin-NG34/CS17 protein in the Western Blot image.
-6xHis-tag Western Blot of the amount of flagellin-NG34/CS17 protein contained in
ni larvae (5 mL loaded), (2 and 9) TSP extract from rBac TB3.2 flagellin-NG34/CS17
ng/lane, respectively). Arrows indicate the bands corresponding to flagellin-NG34/
interpretation of the references to colour in this figure legend, the reader is referred
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ens twice flagellin-NG34/CS17 vaccinated (group B) (Fig. 3B). Only
one chicken showed apathy and was euthanized at 6 dpi. One morechicken from that group also manifested signs of sickness at 8 dpi
(ruffled feathers and mucus secretions) but recovered. In contrast,
all animals from the unvaccinated group (group A) and from the
3420 M. Sisteré-Oró et al. / Vaccine 38 (2020) 416–422once flagellin-NG34/CS17 vaccinated group (group C) were found
sick with signs of apathy right from the first day of challenge. Sta-
tistically significant differences were found in nearly all time-
points when comparing the unvaccinated (group A) with the twice
flagellin-NG34/CS17 vaccinated group (group B). Apathy in chick-
ens from both A and B groups appreared more severe as one animal
died at 2 dpi and other 2 at 5 dpi regarding the unvaccinated
(group A), and two chickens died at 5 and at 6 dpi concerning
the once flagellin-NG34/CS17 vaccinated (group C). Signs of
flu-like sickness were more apparent and severe that obliged to
sacrifice most of the unvaccinated and once flagellin-NG34/CS17
vaccinated chickens at 7 and 8 dpi [15].
Significant differences were observed in the viral shedding both
from oropharynx and cloaca of chickens twice vaccinated with
flagellin-NG34/CS17 (Fig. 3C and 3D). While the chickens twice
vaccinated with flagellin-NG34/CS17 had viral RNA detection val-
ues almost at the basal level, the unvaccinated group and the
flagellin-NG34/CS17 once vaccinated group showed variations that
peaked at 7 dpi (both orally and cloacally). Regarding OS, statisti-
cally significant differences in the mean values of log10 GEC/mL
among twice vaccinated and unvaccinated groups were noticed
at 7 dpi at 9 dpi (P < 0.01) (Fig. 3C). Similarly, cloacal viral shedding
from unvaccinated and once vaccinated animals was in higher
number than the twice vaccinated ones. At 7 dpi, significant differ-
ences (P < 0.001) in the mean values among unvaccinated and
flagellin-NG34/CS17 twice vaccinated groups were detected
(Fig. 3D). It should be noted that only two chickens remained alive
from unvaccinated challenged and once flagellin-NG34/CS17 vacci-
nated groups at 9 dpi. Concerning the unvaccinated group, viral
secretion in OS, as recorded by RT-qPCR, was observed in both
chickens, while viral secretion from CS was detected only from
one of the two animals.
Flagellin-NG34/CS17 twice vaccinated chicken (group B) dis-
played a higher mean of IgM antibodies against H7 in sera at 33
PVD and 10 dpi than the unvaccinated and once flagellin-NG34/
CS17 vaccinated chickens (Fig. 3E). IgY antibody levels, on the
other hand, were accelerated slightly in the flagellin-NG34/CS17
twice vaccinated chickens at 33 PVD though this tendency was
not maintained at 10 dpi. In fact, higher mean of IgY antibodies
at 10 dpi were observed in the unvaccinated chickens rather than
in the once or twice flagellin-NG34/CS17 vaccinated (Fig. 3F). This
tendency may attribute to the fact that only two unvaccinated
chickens remained alive on 9 dpi and one of them showed higher
amount of antibodies.Fig. 3. (A) Survival rates (%) of the different treatment groups are after challenge with
depicted by grey circles, Group B (animals 13–24; flagellin-NG34/CS17; vaccinated twice
NG34/CS17; vaccinated once with flagellin-NG34/CS17) by black triangles. The significa
with log-rank (Mantel-Cox) test. Statistically significant difference concerning survival a
(P < 0.01) among Group B and Group C is depicted as: **. (B) Mean scoring of the flu-like cl
24; vaccinated twice with flagellin-NG34/CS17; black bars) and group C (animals 25–34;
checker bars) plotted from 1 to 10 dpi. Dpi, days post-inoculation. Rates above the bars
Error bars represent the mean ± SEM. One-way ANOVA followed by Dunnett’s multi
Statistically significant difference concerning OD values among groups (P value < 0.05) is
from oral swabs (D) and cloacal swabs; sampled at 0, 1, 2, 3, 5, 7 and 9 dpi from Group A
with flagellin-NG34/CS17 vaccinated; black bars) and Group C (animals 25–34; flagellin
bars) detected by RT-qPCR. Dpi, days post-inoculation. GEC, genomic equivalent copies. R
chickens examined. Dashed line marks the detection limit of the technique: 0.84 log10GE
multiple test was employed (assigning as control group: group A, the unvaccinated). Sta
are depicted as *** P < 0.001, **:P < 0.01. (E) Individual and group mean of IgM HA-specifi
Group A (animals 1–12; unvaccinated; grey circles), Group B (animals 13–24; vaccina
flagellin-NG34/CS17; vaccinated once with flagellin-NG34/CS17; by black and white chec
post-inoculation. Error bars indicate the mean ± SEM. One-way ANOVA followed by D
unvaccinated).3.3. Flagellin-NG34/CS17 failed to induce HI and SNT titers against
H7N1
HI and SNT titers were negative in the three groups. An HI titer
of 1:80 was only observed in only one flagellin-NG34/CS17 twice
vaccinated chicken that also showed flu-like clinical symptoms
and recovered later.4. Discussion
Immunization of poultry is vital as a prophylactic method when
there is risk of IVs incursion and when the areas are endemic to
such viruses. In the present study, two conserved HA-epitopes
(NG-34 and CS-17) selected by in silico prediction were linked
and used as vaccine candidates. The NG-34 peptide belongs to a
highly conserved region of the HA, the E domain [17]. The CS-17
peptide, corresponds to the cleavage site of the HA from H5
HPAIVs. Previous immunization studies using polypeptide cover-
ing the cleavage site from IV subytpes A and B have elicited neu-
tralizing antibody responses and conferred protection in mice
[18,19]. Additionally, flagellin was fused to HA-epitopes (NG-34
and CS-17) in order to enhance their immunogenicity. Similar
studies were also carried out previously with flagellin ligand in
IV vaccines as effective adjuvants for poultry [20,21].
More than the 80% of chickens vaccinated twice survived the
IVs challenge reducing significantly the virus load in oropharyngeal
and cloacal mucosal tissues. This is in accordance with the stan-
dard set by OIE [15]. We are aware that a higher viral dose must
be used to achieve a 90% of the mortality in the unvaccinated chal-
lenged animal group. However, it should be taken into account that
one of the two survivors in the unvaccinated group showed deteri-
orated signs of sickness and most probably needed euthanization.
Protection against IVs is generally attributed to anti-HA anti-
bodies, determined by ELISA, HI and SNT [22]. In this study,
hemaglutination-inhibiting/neutralizing antibodies were either
very low or below detection levels. Elevated IgM antibody levels
in the flagellin-NG34/CS17 twice vaccinated group were recorded.
We assume that simple ELISA test detect also lower affinity anti-
bodies that are missed in HI or neutralization assays [23]. There
is however, no consensus of the ELISA titers required in order to
achieve protection [24]. Protection without the need of high HI
and/or neutralizing titers against H7 subtype IVs has been
described previously [25,26]. Reports indicate that candidate0.1 mL of 104.5ELD50 of a H7N1 HPAIV. Group A (animals 1–12; unvaccinated) is
with flagellin-NG34/CS17) by black squares and Group C (animals 25–34; flagellin-
nce between the survival curves was determined by Kaplan-Meier survival analysis
mong Group A and Group B (P < 0.001) is depicted as ***: The significant difference
inical signs of group A (unvaccinated animals 1–12; grey bars), group B (animals 13–
flagellin-NG34/CS17; vaccinated once with flagellin-NG34/CS17; by black and white
indicate the relation between positive chickens and the total of chickens examined.
ple test was employed (assigning as control group: group A, the unvaccinated).
marked as *: P < 0.05. (C) Mean of genomic equivalent copies (GEC) per mL obtained
(animals 1–12; unvaccinated; grey bars), Group B (animals 13–24; vaccinated twice
-NG34/CS17; vaccinated once with flagellin-NG34/CS17; black and white checker
ates above the bars indicate the relation between positive chickens and the total of
C/mL. Error bars represent the mean ± SEM. One-way ANOVA followed by Dunnett’s
tistically significant differences concerning shedding among groups (P value < 0.05)
c and (F) of IgY antibody levels detected in sera samples at 33 PVD and 10 DPI from
ted twice with flagellin-NG34/CS17; black squares) and Group C (animals 25–34;
ker bars) by ELISA test. OD, optical density. PVD, post-vaccination days and DPI, days
unnett0s multiple test was employed (assigning as control group: group A, the
M. Sisteré-Oró et al. / Vaccine 38 (2020) 416–422 421inactivated vaccines against potential pandemic viruses (H5/H7)
have induced low immunogenicity, required two doses as well as
adjuvant in their composition. Possible explanations of these low
inhibiting/neutralizing titers are focused on the levels of glycosyla-
tion of the HA protein [27,28].
Previous reports also suggest that non-neutralizing antibodies
may confer protection against IVs [22,29]. These antibodies either
interact with the complement [30] or recruit NK cells/monocytes
leading to kill IV-infected cells by antibody-dependent cellular
cytotoxicity (ACDD) [31]. IgM antibodies, on the other hand, could
neutralize IVs as efficiently as IgY antibodies in the presence of
complement [32]. Experiments with passive serum transfer from
vaccinated to naïve chicken may unravel the mechanism of anti-
body induced protection. Possible involvement of cellular immune
response in flagellin-NG34/CS17-associated protection in chicken
against IVs challenge is under investigation. In our previous work
we showed that NG-34 peptide included in the vaccine formula-
tion induces strong T cell response [9].
In conclusion, flagellin-NG34/CS17 may serve as a potential
vaccine to protect against heterologous IV infections in chicken.
It further limits IVs transmission by blocking virus shedding from
vaccinated animals. Further experiments are needed to understand
completely the immune mechanisms associated to the protection
conferred. Whether this vaccine would protect animals from other
HPAIV infections is currently under investigation.5. Author0s contributions
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